United Therapeutics Corporation (UTHR)
Company Info
Highlights
$14.45B
$25.47
12.58
1.43
$2.99B
$2.66B
$1.56B
$266.98 - $417.82
$388.18
6.10%
4.81
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
Loading data...
Returns By Period
United Therapeutics Corporation (UTHR) returned -9.20% year-to-date (YTD) and 19.67% over the past 12 months. Over the past 10 years, UTHR returned 5.81% annually, underperforming the S&P 500 benchmark at 10.84%.
UTHR
-9.20%
6.52%
-15.28%
19.67%
10.75%
22.12%
5.81%
^GSPC (Benchmark)
0.52%
6.32%
-1.44%
12.25%
12.45%
14.20%
10.84%
Monthly Returns
The table below presents the monthly returns of UTHR, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | -0.47% | -8.86% | -3.68% | -1.68% | 5.70% | -9.20% | |||||||
| 2024 | -2.32% | 5.06% | 1.81% | 2.01% | 17.41% | 15.78% | -1.65% | 16.04% | -1.43% | 4.36% | -0.93% | -4.76% | 60.46% |
| 2023 | -5.37% | -6.51% | -8.97% | 2.75% | -8.86% | 5.25% | 9.95% | -7.56% | 0.67% | -1.33% | 7.69% | -8.38% | -20.93% |
| 2022 | -6.58% | -17.67% | 7.95% | -1.03% | 29.73% | 2.30% | -1.94% | -1.93% | -7.61% | 10.10% | 21.41% | -0.64% | 28.70% |
| 2021 | 7.93% | 2.05% | 0.05% | 20.50% | -7.77% | -3.49% | 1.40% | 18.11% | -14.10% | 3.35% | -0.66% | 14.03% | 42.35% |
| 2020 | 10.89% | 5.42% | -7.90% | 15.54% | 7.66% | 2.59% | -7.88% | -4.05% | -5.57% | 32.90% | -1.18% | 14.44% | 72.33% |
| 2019 | 5.90% | 9.50% | -7.06% | -12.61% | -18.13% | -7.04% | 1.51% | 4.19% | -3.40% | 12.65% | 2.69% | -4.53% | -19.12% |
| 2018 | -12.81% | -10.19% | -3.01% | -2.00% | -3.21% | 6.16% | 8.63% | 0.07% | 3.98% | -13.31% | 6.53% | -7.79% | -26.39% |
| 2017 | 14.08% | -9.72% | -8.35% | -7.15% | -3.83% | 7.31% | -1.03% | 1.87% | -10.41% | 1.19% | 9.61% | 13.82% | 3.15% |
| 2016 | -21.35% | -1.01% | -8.62% | -5.59% | 13.18% | -11.04% | 14.25% | 1.05% | -3.43% | 1.69% | 4.61% | 14.19% | -8.42% |
| 2015 | 8.99% | 9.86% | 11.21% | -7.39% | 15.05% | -5.32% | -2.64% | -11.07% | -12.87% | 11.73% | 4.09% | 2.61% | 20.94% |
| 2014 | -9.25% | -1.17% | -7.29% | 6.36% | -4.27% | -7.57% | 2.77% | 29.57% | 9.18% | 1.80% | 1.22% | -2.32% | 14.51% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of UTHR is 68, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for United Therapeutics Corporation (UTHR) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Loading data...
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading data...
Worst Drawdowns
The table below displays the maximum drawdowns of the United Therapeutics Corporation. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the United Therapeutics Corporation was 93.18%, occurring on Dec 10, 2001. Recovery took 2282 trading sessions.
The current United Therapeutics Corporation drawdown is 21.86%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -93.18% | Jul 13, 2000 | 352 | Dec 10, 2001 | 2282 | Jan 3, 2011 | 2634 |
| -60.3% | Apr 24, 2015 | 1068 | Jul 22, 2019 | 428 | Apr 1, 2021 | 1496 |
| -60.2% | Feb 28, 2000 | 36 | Apr 17, 2000 | 51 | Jun 29, 2000 | 87 |
| -47.37% | Apr 28, 2011 | 110 | Oct 3, 2011 | 451 | Jul 22, 2013 | 561 |
| -31.98% | Nov 11, 2024 | 103 | Apr 10, 2025 | — | — | — |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading data...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of United Therapeutics Corporation over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Earnings Per Share
The chart presents the Earnings Per Share (EPS) performance of United Therapeutics Corporation, comparing actual results with analytics estimates. The company met analyst expectations for EPS in the past quarter.
Valuation
The Valuation section provides an overview of how United Therapeutics Corporation is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for UTHR, comparing it with other companies in the Biotechnology industry. Currently, UTHR has a P/E ratio of 12.6. This P/E ratio is in line with the industry average, suggesting the stock may be fairly valued relative to its earnings.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for UTHR compared to other companies in the Biotechnology industry. UTHR currently has a PEG ratio of 1.4. This PEG ratio is close to the industry average, suggesting the stock’s valuation is balanced against its growth outlook.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for UTHR relative to other companies in the Biotechnology industry. Currently, UTHR has a P/S ratio of 4.8. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for UTHR in comparison with other companies in the Biotechnology industry. Currently, UTHR has a P/B value of 2.1. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |